Genmab — November 2017
-
status separately for each indication they intend to label the drug for.
Breakthrough designation applications are submitted as an amendment to the IND applications before the initiation of clinical trials.[9]
-
-
hvornår har han sagt det, jeg hørte det ikke???
-
Det sagde han også i august! Så det skal nok tages med et gran salt.
-
sagde han det i går??
-
- Når jeg ser på receptdata fra IMS for oktober, så virker salget i oktober til at blive den bedste måned nogensinde, og ifølge vores partner Janssen (Johnson & Johnsons datterselskab, red.), så er lanceringen af Darzalex den hurtigste og mest effektive, der nogensinde har været af et middel mod knoglemarvskræft, siger Jan van de Winkel. kilde Nordnet
nohopeHello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind